Evolus, Inc.

Evolus, Inc. operates as a global performance beauty company primarily focused on the cash-pay aesthetic market, which involves medical products directly paid for by consumers. The company's business model centers on delivering breakthrough products with a customer-centric approach, leveraging flexibility derived from an aesthetic-only, non-reimbursed product strategy to drive customer adoption through loyalty programs, co-branded marketing, promotional events, and pricing strategies. Its customers are aesthetic practitioners licensed to administer the products.

The core business model revolves around the sale of injectable neurotoxins and injectable hyaluronic acid (HA) gels, which are two of the largest and fastest-growing segments in the global aesthetics market. The company generates revenue from product sales and, to a lesser extent, service revenue from distribution partners. Revenue recognition occurs when control of goods is transferred to the customer, or when services are performed for the expected consideration. Product revenues are reported net of adjustments for customer rebates, consumer loyalty program rewards, and co-branded marketing programs.

Evolus's product portfolio includes Jeuveau®, a proprietary 900 kilodalton (kDa) purified botulinum toxin type A formulation, indicated for the temporary improvement of moderate to severe glabellar lines in adults. Jeuveau® is available in the United States, Canada, certain European markets, and Australia. The company also offers the Evolysse™ collection of injectable HA gels, which utilizes first-generation cold technology and includes products for mid-face, nasolabial folds, lips, and eyes. In February 2025, Evolysse™ Form and Evolysse™ Smooth received FDA approval for wrinkles and folds, such as nasolabial folds, and were launched in the U.S. in April 2025.

For the fiscal year ended December 31, 2025, Evolus reported total net revenues of $297.176 million ¹, an increase of 11.6% from $266.274 million ² in 2024. Product revenue, net, was $294.956 million ³, while service revenue contributed $2.220 million ⁴. Cost of goods sold increased by 19.2% to $100.069 million ⁵ from $83.970 million ⁶ in the prior year, primarily due to increased sales volume of both Jeuveau® and Evolysse™. Gross profit for 2025 was $197.107 million ⁷, with a gross profit margin of 66.3% ⁸, down from 68.5% ⁹ in 2024. Operating expenses totaled $229.769 million ¹⁰, leading to a loss from operations of $32.662 million ¹¹. The company reported a net loss of $51.641 million ¹² for 2025, compared to $50.420 million ¹³ in 2024. Diluted EPS was $(0.80) ¹⁴ for 2025, compared to $(0.81) ¹⁵ in 2024. Cash and cash equivalents stood at $53.826 million ¹⁶ as of December 31, 2025, with a total indebtedness of $150.0 million ¹⁷ in principal amount.

Year-over-year, total net revenues grew by $30.9 million ¹⁸, or 11.6% ¹⁹, driven by the U.S. launch of Evolysse™ and increased Jeuveau® sales. Product revenue from Jeuveau® was $272.323 million ²⁰ in 2025, while Evolysse™ contributed $22.633 million ²¹ in its launch year. Gross profit margin contracted from 68.5% ⁹ to 66.3% ⁸. Selling, general and administrative expenses increased by $22.8 million ²², or 11.5% ²³, to $220.786 million ²⁴, mainly due to higher personnel costs for commercial activities and training for the Evolysse™ launch. Research and development expenses also saw a slight increase of $0.4 million ²⁵, or 4.4% ²⁶, reaching $9.576 million ²⁷.

Significant operational developments during the period include the FDA approval of Evolysse™ Form and Evolysse™ Smooth in February 2025, followed by their U.S. launch in April 2025. In August 2025, the company submitted a Premarket Approval Application (PMA) to the FDA for Evolysse™ Sculpt. A strategic cost structure optimization was performed in the third quarter of 2025, incurring $1.4 million ²⁸ in restructuring costs, primarily for one-time separation benefits. In May 2025, Evolus entered into an Amended and Restated Loan Agreement with Pharmakon, providing up to $250.0 million ²⁹ in senior secured term loans, with an initial tranche of $150.0 million ³⁰ funded upon execution.

Evolus anticipates continued sales growth, which will be dependent on several factors, including its ability to expand its customer base and increase purchases by existing customers within the competitive aesthetic market. Key growth drivers also include the sustained success of Evolysse™ Form and Evolysse™ Smooth products in the United States, the upcoming commercial launch of the full Evolysse™ injectable HA gel collection in Europe, and the regulatory approval of Evolysse™ Sculpt and Evolysse™ Lips products in the United States.

The company expects to launch all four Evolysse™ products in Europe in the second quarter of 2026. Furthermore, it anticipates that two additional Evolysse™ products, Evolysse™ Sculpt and Evolysse™ Lips, will be approved in the United States in 2026 and 2027, respectively. The Premarket Approval Application (PMA) for Evolysse™ Sculpt was submitted in August 2025, with FDA approval expected in the second half of 2026.

Operationally, Evolus expects its gross profit margin to fluctuate due to changes in product and geographic mix, as well as the impact of promotional and incentive programs on average selling prices. Selling, general and administrative expenses may fluctuate in the future, primarily driven by potential changes in marketing strategies, launches of new products, and international expansion. Research and development expenses are expected to continue to increase as the company develops further product candidates and pursues regulatory approvals.

Regarding capital allocation, Evolus believes its current capital resources, including cash and cash equivalents, future cash generated from operations, and the availability of an additional $100.0 million ³¹ in liquidity under the New Pharmakon Term Loans, along with the recently closed Revolving Credit Facility, will be sufficient to meet its cash requirements for at least the next twelve months. The company's future funding requirements are dependent on factors such as the revenue growth rate for Jeuveau® and Evolysse™, the timing of regulatory approvals and commercialization success for additional Evolysse™ products, development costs and milestone payments for Evolysse™ products, and the ability to forecast demand and manage working capital. The company also plans for corporate development activities, including the purchase, license, or acquisition of additional products and services.

Structural headwinds and execution risks management explicitly flagged include the dynamic and uncertain tariff environment, which has already increased the cost of goods for products sourced from France and South Korea. There is a risk that the U.S. Department of Commerce's investigation into pharmaceutical imports could lead to significant tariffs on products like Jeuveau®. The company's reliance on consumer discretionary spending makes it sensitive to global economic conditions, including inflationary pressures and weakening consumer confidence, which have negatively impacted aesthetic procedures and sales. The company also faces intense competition in the medical aesthetics market from larger, more experienced companies with greater financial resources, brand recognition, and product portfolios, which could lead to price-cutting and reduced profit margins. Furthermore, the company's exclusive focus on the cash-pay healthcare market limits its ability to offer reimbursed products or expand into therapeutic indications, potentially restricting sales growth and profitability.

Evolus faces several material risks, including significant ongoing losses, with a net loss of $51.641 million ¹² in 2025 and an accumulated deficit of $661.0 million ³². The company operates in a highly competitive medical aesthetics market, where its products, Jeuveau® and Evolysse™, compete with larger, more established companies that possess greater financial resources, brand recognition, and broader product portfolios, potentially leading to aggressive pricing, bundling, and reduced profit margins. The business is highly reliant on consumer discretionary spending, making it vulnerable to unpredictable global economic conditions, inflationary pressures, and changes in consumer sentiment, which have already negatively impacted procedural volumes. Trade policy risks, including enacted and threatened tariffs on imports from France and South Korea, could significantly increase costs and harm revenues. The company's reliance on third-party manufacturers, Daewoong for Jeuveau® and Symatese for Evolysse™, exposes it to supply chain disruptions, regulatory compliance issues, and potential termination of exclusive licensing rights if minimum purchase obligations are not met. Intellectual property infringement claims are a persistent threat, potentially leading to costly litigation, substantial damages, or the need to obtain expensive licenses. Regulatory risks are substantial, with the company subject to extensive government regulation in the U.S., Europe, and other countries, and any failure to comply or delays in obtaining approvals for new indications could result in significant penalties, marketing restrictions, or product recalls. Cybersecurity incidents and information system failures pose a risk to operations, customer order processing, and data security, potentially leading to reputational damage and financial losses. The company's ability to use its federal net operating loss carryforwards of $330.5 million ³³ and state NOLs of $257.8 million ³⁴ may be limited by ownership changes under Section 382 of the Internal Revenue Code.

Management's message to shareholders emphasizes the company's position as a global performance beauty company focused on delivering breakthrough products in the cash-pay aesthetic market with a customer-centric approach. They highlight the flexibility derived from an aesthetic-only, non-reimbursed product strategy as a unique value proposition. The strategic priorities for the period ahead include growing the customer base and increasing purchases by current customers in the competitive aesthetic market, ensuring the continued success of Evolysse™ Form and Evolysse™ Smooth products in the United States, successfully executing the commercial launch of the Evolysse™ injectable HA gel collection in Europe, and securing regulatory approval for Evolysse™ Sculpt and Evolysse™ Lips products in the United States. Management explicitly states the expectation to launch all four Evolysse™ products in Europe in the second quarter of 2026 and anticipates FDA approval for Evolysse™ Sculpt in the second half of 2026, followed by Evolysse™ Lips in 2027. They also note the belief that current capital resources, including cash and cash equivalents, future cash generated from operations, and the availability of an additional $100.0 million ³¹ in liquidity under the New Pharmakon Term Loans and the recently closed Revolving Credit Facility, will be sufficient to fund operations for at least the next twelve months.